The role of tumor necrosis factor alpha in the pathophysiology of congestive heart failure

Current Cardiology Reports

Volumn 2, Issue 3, 2000, Pages 189-197

  McTiernan, Charles F ^a   Feldman, Arthur M ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; NONSTEROID ANTIINFLAMMATORY AGENT; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL; BLOOD; CONGESTIVE HEART FAILURE; CYTOLOGY; DOWN REGULATION; HEART MUSCLE; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOWN-REGULATION; HEART FAILURE, CONGESTIVE; HUMANS; IMMUNOGLOBULIN G; MYOCARDIUM; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034184422     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-000-0068-4     Document Type: Article

References (70)

1. Bristow MR, Ginsburg R, Umans V, et al. : Beta 1-and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 1986, 59:297-309.
2. Takahashi T, Allen PD, Izumo S: Expression of A-, B-, and C-type natriuretic peptide genes in failing and developing human ventricles. Correlation with expression of the Ca(2+)-ATPase gene. Circ Res 1992, 71:9-17.
3. Mercadier JJ, Lompre AM, Duc P, et al. : Altered sarcoplasmic reticulum Ca2(+)-ATPase gene expression in the human ventricle during end-stage heart failure. J Clin Invest 1990, 85:305-309.
4. Feldman AM, Ray PE, Silan CM, et al. : Selective gene expression in failing human heart. Quantification of steady-state levels of messenger RNA in endomyocardial biopsies using the polymerase chain reaction. Circulation 1991, 83:1866-1872.
5. Brillantes AM, Allen P, Takahashi T, et al. : Differences in cardiac calcium release channel (ryanodine receptor) expression in myocardium from patients with end-stage heart failure caused by ischemic versus dilated cardiomyopathy [published erratum appears in Circ Res 1992, 71:1538]. Circ Res 1992, 71:18-26.
6. Studer R, Reinecke H, Bilger J, et al. : Gene expression of the cardiac Na(+)-Ca2+ exchanger in end-stage human heart failure. Circ Res 1994, 75:443-453.
7. Nakao K, Minobe W, Roden R, et al. : Myosin heavy chain gene expression in human heart failure. J Clin Invest 1997, 100:2362-2370.
8. Lowes BD, Minobe W, Abraham WT, et al. : Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest 1997, 100:2315-2324.
9. Li YY, Feldman AM, Sun Y, McTiernan CF: Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 1998, 98:1728-1734.
10. de Belder AJ, Radomski MW, Why HJ, et al. : Myocardial calcium-independent nitric oxide synthase activity is present in dilated cardiomyopathy, myocarditis, and postpartum cardiomyopathy but not in ischaemic or valvar heart disease. Br Heart J 1995, 74:426-430.
11. Haywood GA, Tsao PS, von der Leyen HE, et al. : Expression of inducible nitric oxide synthase in human heart failure [see comments]. Circulation 1996, 93:1087-1094.
12. Haunstetter A, Izumo S: Apoptosis: basic mechanisms and implications for cardiovascular disease. Circ Res 1998, 82:1111-1129.
13. Carswell EA, Old LJ, Kassel RL, et al. : An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975, 72:3666-3670.
14. Beutler B, Greenwald D, Hulmes JD, et al. : Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 1985, 316:552-554.
15. Black RA, Rauch CT, Kozlosky CJ, et al. : A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997, 385:729-733.
16. Vassalli P: The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992, 10:411-452.
17. Dembic Z, Loetscher H, Gubler U, et al. : Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences. Cytokine 1990, 2:231-237.
18. Engelmann H, Novick D, Wallach D: Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem 1990, 265:1531-1536.
19. Seckinger P, Isaaz S, Dayer JM: A human inhibitor of tumor necrosis factor alpha. J Exp Med 1988, 167:1511-1516.
20. Levine B, Kalman J, Mayer L, et al. : Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990, 323:236-241.
21. Torre-Amione G, Kapadia S, Benedict C, et al. : Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996, 27:1201-1206.
22. Testa M, Yeh M, Lee P, et al. : Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 1996, 28:964-971.
23. Ferrari R, Bachetti T, Confortini R, et al. : Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure [see comments]. Circulation 1995, 92:1479-1486.
24. Torre-Amione G, Kapadia S, Lee J, et al. : Tumor necrosis factoralpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996, 93:704-711.
25. Badorff C, Noutsias M, Kuhl U, Schultheiss HP: Cell-mediated cytotoxicity in hearts with dilated cardiomyopathy: correlation with interstitial fibrosis and foci of activated T lymphocytes. J Am Coll Cardiol 1997, 29:429-434.
26. Habib FM, Springall DR, Davies GJ, et al. : Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy [see comments]. Lancet 1996, 347:1151-1155.
27. Kapadia S, Lee J, Torre-Amione G, et al. : Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest 1995, 96:1042-1052.
28. Wagner DR, McTiernan C, Sanders VJ, Feldman AM: Adenosine inhibits lipopolysaccharide-induced secretion of tumor necrosis factor-alpha in the failing human heart. Circulation 1998, 97:521-524.
29. Wagner DR, Combes A, McTiernan C, et al. : Adenosine inhibits lipopolysaccharide-induced cardiac expression of tumor necrosis factor-alpha. Circ Res 1998, 82:47-56.
30. Kapadia SR, Oral H, Lee J, et al. : Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium. Circ Res 1997, 81:187-195.
31. Torre-Amione G, Stetson SJ, Youker KA, et al. : Decreased expression of tumor necrosis factor-alpha in failing human myocardium after mechanical circulatory support : A potential mechanism for cardiac recovery. Circulation 1999, 100:1189-1193.
32. Irwin MW, Mak S, Mann DL, et al. : Tissue expression and immunolocalization of tumor necrosis factor-alpha in postinfarction dysfunctional myocardium. Circulation 1999, 99:1492-1498.
33. Grosjean SA, Arstall MA, Mitchell RN, et al. : Inducible nitric oxide synthase and tumor necrosis factor in animal models of myocardial necrosis induced by coronary artery ligation or isoproterenol injection. J Card Fail 1999, 5:236-245.
34. Krown KA, Yasui K, Brooker MJ, et al. : TNF alpha receptor expression in rat cardiac myocytes: TNF alpha inhibition of L-type Ca2+ current and Ca2+ transients. FEBS Lett 1995, 376:24-30.
35. Murray DR, Freeman GL: Tumor necrosis factor-alpha induces a biphasic effect on myocardial contractility in conscious dogs. Circ Res 1996, 78:154-160.
36. Finkel MS, Oddis CV, Jacob TD, et al. : Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992, 257:387-389.
37. Goldhaber JI, Kim KH, Natterson PD, et al. : Effects of TNFalpha on [Ca2+]i and contractility in isolated adult rabbit ventricular myocytes. Am J Physiol 1996, 271:H1449-H1455.
38. Yokoyama T, Vaca L, Rossen RD, et al. : Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest 1993, 92:2303-2312.
39. Chung MK, Gulick TS, Rotondo RE, et al. : Mechanism of cytokine inhibition of beta-adrenergic agonist stimulation of cyclic AMP in rat cardiac myocytes. Impairment of signal transduction. Circ Res 1990, 67:753-763.
40. Stein B, Frank P, Schmitz W, et al. : Endotoxin and cytokines induce direct cardiodepressive effects in mammalian cardiomyocytes via induction of nitric oxide synthase. J Mol Cell Cardiol 1996, 28:1631-1639.
41. Yokoyama T, Nakano M, Bednarczyk JL, et al. : Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 1997, 95:1247-1252.
42. Li YY, McTiernan CF, Feldman AM: Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells. Cardiovasc Res 1999, 42:162-172.
43. Gulick T, Chung MK, Pieper SJ, et al. : Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. Proc Natl Acad Sci U S A 1989, 86:6753-6757.
44. Krown KA, Page MT, Nguyen C, et al. : Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 1996, 98:2854-2865.
45. Tracey KJ, Vlassara H, Cerami A: Cachectin/tumour necrosis factor. Lancet 1989, 1:1122-1126.
46. Kubota T, McTiernan CF, Frye CS, et al. : Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 1997, 81:627-635.
47. Kubota T, Bounoutas GS, Miyagishima M, et al. : Soluble Tumor necrosis factor receptor abrogates myocardial inflammation but not hypertrophy in cytokine-induced cardiomyopathy. Circulation 2000, in press.
48. Li YY, Feng YQ, Kadokami T, et al. : Modulation of matrix metalloproteinase activites remodels myocardial extracellular matrix in TNF-alpha transgenic mice. Circulation 1999, 100:I-752.
49. Kubota T, Bounoutas GS, Miyagishima M, et al. : Development of myocarditis in transgenic mice overexpressing tumor necrosis factor-alpha is mediated in part by the selctive induction of downstream proinflammatory cytokines and beta-chemokines. Circulation 1998, 98:I-345.
50. Kubota T, Miyagishima M, Bounoutas GS, et al. : Overexpression of tumor necrosis factor-alpha activates the expression of multiple members of the apoptosis pathway in transgenic mice. Circulation 1998, 98:I-462.
51. Pan X, Baker L, Lee JS, et al. : Atrial and ventricular arrhythmias in transgenic mice with myocardial expression of TNF-alpha. Circulation 1998, 98:I-745.
52. Dibbs ZL, Kalra D, Abdellatif M, et al. : Different cardiac phenotypes of secreted and membrane-bound TNF in transgenic mouse models of cardiac restricted overexpression of TNF. Circulation 1999, 100:I-16.
53. Bryant D, Becker L, Richardson J, et al. : Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha [see comments]. Circulation 1998, 97:1375-1381.
54. Bozkurt B, Kribbs SB, Clubb FJ Jr, et al. : Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998, 97:1382-1391.
55. Oral H, Dorn GW 2nd, Mann DL: Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian cardiac myocyte. J Biol Chem 1997, 272:4836-4842.
56. Sabbadini RA, Betto R, Teresi A, et al. : The effects of sphingosine on sarcoplasmic reticulum membrane calcium release. J Biol Chem 1992, 267:15475-15484.
57. Francis SE, Holden H, Holt CM, Duff GW: Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy. J Mol Cell Cardiol 1998, 30:215-223.
58. Thaik CM, Calderone A, Takahashi N, Colucci WS: Interleukin-1 beta modulates the growth and phenotype of neonatal rat cardiac myocytes. J Clin Invest 1995, 96:1093-1099.
59. McTiernan CF, Lemster BH, Frye C, et al. : Interleukin-1 beta inhibits phospholamban gene expression in cultured cardiomyocytes. Circ Res 1997, 81:493-503.
60. Clerk A, Harrison JG, Long CS, Sugden PH: Pro-inflammatory cytokines stimulate mitogen-activated protein kinase subfamilies, increase phosphorylation of c-Jun and ATF2 and upregulate c-Jun protein in neonatal rat ventricular myocytes [In Process Citation]. J Mol Cell Cardiol 1999, 31:2087-2099.
61. Sugden PH, Clerk A: "Stress-responsive" mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogenactivated protein kinases) in the myocardium. Circ Res 1998, 83:345-352.
62. Kyriakis JM: Making the connection: coupling of stressactivated ERK/MAPK (extracellular-signal-regulated kinase/mitogen-activated protein kinase) core signaling modules to extracellular stimuli and biological responses. Biochem Soc Symp 1999, 64:29-48.
63. Saklatvala J, Dean J, Finch A: Protein kinase cascades in intracellular signalling by interleukin-I and tumour necrosis factor. Biochem Soc Symp 1999, 64:63-77.
64. Wooley PH, Dutcher J, Widmer MB, Gillis S: Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993, 151:6602-6607.
65. Moreland LW, Schiff MH, Baumgartner SW, et al. : Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999, 130:478-486.
66. Deswal A, Bozkurt B, Seta Y, et al. : Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure [see comments]. Circulation 1999, 99:3224-3226.
67. Bozkurt B, Torre-Aminoe G, Deswal A, et al. : Regression of left ventricular remodleing in chronic heart failure after treatment with ENBREL (Etanercept, p75 TNF receptor Fc Fusion protein). Circulation 1999, 100:I-645.
68. Sliwa K, Skudicky D, Candy G, et al. : Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet 1998, 351:1091-1093.
69. Oliver SJ, Freeman SL, Corral LG, et al. : Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis. Clin Exp Immunol 1999, 118:315-321.
70. Dibbs ZL, Longo T, Muller GW, et al. : Thalidomide and thalidomide analogs suppress TNF alpha secretion by myocytes. Circulation 1998, 98:I-247.